TD Cowen analyst Ritu Baral downgraded AN2 Therapeutics (NASDAQ: ANTX) from Buy to Hold.The analyst comments: "3Q24: Ph2 EBO topline ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE